Back to Search
Start Over
333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer
333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer
- Source :
- Annals of Oncology. 32:S511-S512
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
Details
- ISSN :
- 09237534
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........2dc19defaaeca4a92638bfecf62dc907
- Full Text :
- https://doi.org/10.1016/j.annonc.2021.08.616